Keyword: AbbVie

A judge questioned the Justice Department's motives for dismissing whistleblower allegations that UCB paid kickbacks to boost Cimzia scripts.

Pharmaceutical ad spending continued its upward climb last year, with spending topping $6.46 billion, according to Kantar Media.

AbbVie and Shire investors struck an agreement to settle claims AbbVie misled the public about its reasons for pursuing Shire.

J&J, Merck, Pfizer and Abbott reaped a combined $7 billion in savings from two tax reform provisions, and they spent most of it on investor payouts.

AbbVie’s Humira and Pfizer’s Xeljanz remained in the top two spots for pharma TV ad spending for the month of March.

Plaintiffs are piling into court claiming AbbVie quashed Humira competition with a "patent thicket" and an illegal “pay-for-delay" deal.

AbbVie investors are calling for a separation of powers between its board chairman and CEO roles following congressional scrutiny and patent fights over its drug Humira.

A new investigative report outlines how AbbVie worked to keep Humira market share upon the introduction of biosimilars in the Netherlands.

Louisiana is the first state to adopt a subscription model for prescription drug purchasing—and it's starting out with Gilead's hep C drugs.